Phase 3 Head and Neck Cancer Trial, Recruiting NCT05941741 Sponsor: Sun Yat-sen University Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT05941741
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have recently been diagnosed with a specific type of nasopharyngeal carcinoma (a cancer at the back of the nose/throat) confirmed by tissue biopsy — specifically the non-keratinizing type (classified as WHO Type II or III)
  • People of any gender between 18 and 70 years old
  • People who are generally well enough to carry out normal daily activities with little or no limitation (this is measured by a standard medical performance score)
  • People whose cancer has been staged at a specific advanced level — involving either a large local tumour with limited lymph node spread, or any tumour size with more significant lymph node involvement, but with no spread to distant parts of the body (confirm with trial site for exact staging details)
  • People who have not yet received any cancer treatments, including radiation, chemotherapy, or immunotherapy
  • People who have no medical reasons preventing them from receiving chemotherapy, radiotherapy, or immunotherapy
  • People whose blood counts, liver function, and kidney function all fall within acceptable ranges as measured by standard blood tests
  • People who are willing and able to sign a consent form to participate

Who may not be able to join:

  • People whose cancer has already spread to distant parts of the body (metastases)
  • People diagnosed with a different subtype of the cancer — specifically keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma
  • People who have had, or currently have, another type of cancer
  • People who are already taking part in another clinical trial
  • People who are pregnant or breastfeeding
  • People who have heart or blood vessel disease that is not well controlled
  • People with serious additional health conditions, such as high blood pressure that cannot be adequately controlled
  • People with a diagnosed mental health disorder
  • People with a history of drug or alcohol dependency
  • People who do not have full legal capacity to make decisions for themselves (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Chong Zhao, MD, PhD, Sun Yat-Sen University Cancer Center

Phone: 02087342638

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
10 January 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov